BI 730357(口服RORγt抑制剂)治疗中重度斑块状银屑病的II期随机试验
这项II期双盲随机试验评估口服RORγt抑制剂BI 730357治疗中重度斑块状银屑病,共274例患者分两部分接受不同剂量或安慰剂。药物相关不良事件≤15.8%。长期扩展期93/165例(56.4%)达PASI75,耐受性良好,疗效中等。
要点
- 暴露-效应关系在≥200mg每日一次时趋于平台。
- 药物相关不良事件发生率≤15.8%,长期扩展期耐受性良好。
核心结论
- BI 730357治疗中重度斑块状银屑病耐受性良好,较安慰剂有中等疗效。
研究设计与样本
- II期两部分双盲随机试验,第1部分按2:2:2:2:1随机分配至25、50、100、200mg BI 730357或安慰剂每日一次(空腹)。
- 第2部分另组患者按4:4:1随机分配至400mg每日一次、200mg每日两次或安慰剂(进食)。
- 共274例患者接受治疗(第1部分178例,第2部分96例)。
主要发现
- 暴露-效应关系在≥200mg每日一次时趋于平台。
- 药物相关不良事件发生率≤15.8%。
- 长期扩展期165例中93例(56.4%)达PASI75,药物相关不良事件≤18.5%。
关键数值与推荐
- 共同主要终点为第12周PASI75和sPGA 0/1(清除/几乎清除)。
- 长期扩展期PASI75应答率56.4%(93/165)。
临床怎么用
- BI 730357作为口服RORγt抑制剂,可能为中重度斑块状银屑病提供中等疗效的系统治疗选择。
- 治疗期间需关注药物相关不良事件,长期扩展数据显示耐受性良好。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TRIAL DESIGN: This 2-part, double-blinded trial assessed the RORγt inhibitor BI 730357 in plaque psoriasis. METHODS: In part 1, patients were randomized 2:2:2:2:1 to 25, 50, 100, and 200 mg BI 730357 or placebo once daily (fasting conditions); nonresponders were switched to higher doses. In part 2, a separate patient set was randomized 4:4:1 to receive BI 730357 (400 mg once daily, 200 mg twice daily) or a placebo (fed conditions). Patients from parts 1 and 2 could enter a long-term extension trial. Coprimary endpoints included ≥75% reduction from baseline in PASI75 and static Physician's Global Assessment score of 0/1 (clear/almost clear) at week 12. RESULTS: In total, 274 patients were treated (178 [part 1] and 96 [part 2]). In part 1, 12 (30.0%) patients achieved PASI75 (P = .0062), and 11 (27.5%) achieved static Physician's Global Assessment of 0/1 (P = .0095) with BI 730357 200 mg versus none receiving placebo. Exposure-response relationship plateaued at ≥200 mg once daily BI 730357. Drug-related adverse events occurred in ≤15.8% of patients. Of 165 patients who entered the long-term extension, 93 (56.4%) achieved PASI75 during treatment, and ≤18.5% experienced a drug-related adverse event. CONCLUSIONS: BI 730357 was well tolerated, with moderate efficacy versus placebo in plaque reduction (clinicaltrials.gov: NCT03635099 and NCT03835481).
引用
- Gooderham MJ, Mrowietz U, Kadus W, et al. Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis. J Invest Dermatol. 2025. PMID: 39848568. doi:10.1016/j.jid.2024.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。